| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 0.6373 unch on 04/01/25 |
Period Open: 0.8400
| 0.9639 -33.88% on 03/17/25 | -0.2027 (-24.13%) since 02/28/25 |
| 3-Month | 0.6373 unch on 04/01/25 |
Period Open: 0.9300
| 1.2500 -49.02% on 01/07/25 | -0.2927 (-31.47%) since 12/31/24 |
| 52-Week | 0.6373 unch on 04/01/25 |
Period Open: 0.9041
| 1.9280 -66.95% on 05/13/24 | -0.2668 (-29.51%) since 04/01/24 |
For Immediate ReleaseChicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR...
The biotech industry has declined since Donald Trump’s election victory. This was mainly because Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Health and Human Services, the agency...
Jonathan Zalevsky, the Chief R&D Officer of $NKTR ($NKTR), sold 7,785 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.1%...
This penny stock could surge up to 200%, according to one bull, who has high hopes for a pipeline drug ahead of trial data due out in 2025.
/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg)...
/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close...
/PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023. Cash and investments in...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company. As announced...
-- Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs -- -- Development of NKTR-255 in diffuse...
/PRNewswire/ -- Crane Co. (NYSE:CR) will be added to the S&P MidCap 400 effective prior to the open of trading on Tuesday, April 4, replacing PacWest Bancorp...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today issued a statement confirming that it does not have any accounts at Silicon Valley Bank, and it does...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Cash and...
March S&P 500 futures (ESH23) are down -0.33% and March Nasdaq 100 E-Mini futures (NQH23) are down -0.75% this morning as investors braced for the release of the U.S. personal consumption expenditures...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of...
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Nektar Therapeutics (Nasdaq: NKTR) concerning the Company and its directors’ and officers’ possible violations of state laws.
/PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual...
/PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Cash and...
March S&P 500 futures (ESH23) are down -0.33% and March Nasdaq 100 E-Mini futures (NQH23) are down -0.75% this morning as investors braced for the release of the U.S. personal consumption expenditures...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of...
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Nektar Therapeutics (Nasdaq: NKTR) concerning the Company and its directors’ and officers’ possible violations of state laws.
/PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual...
/PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Cash and...
March S&P 500 futures (ESH23) are down -0.33% and March Nasdaq 100 E-Mini futures (NQH23) are down -0.75% this morning as investors braced for the release of the U.S. personal consumption expenditures...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of...
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Nektar Therapeutics (Nasdaq: NKTR) concerning the Company and its directors’ and officers’ possible violations of state laws.
/PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual...
/PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in...
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the...
| Symbol | %Holdings | 3M %Chg |
|---|---|---|
| NKTR | -31.47% | |
| Nektar Therapeutics | ||
| QQQS | 0.4% | -19.17% |
| Invesco Nasdaq Future Gen 200 ETF | ||
| IWC | 0.04% | -14.99% |
| Micro-Cap Ishares ETF | ||
| GSSC | 0.02% | -8.17% |
| GS Activebeta U.S. Small Cap Equity ETF | ||
| PRFZ | 0.02% | -8.87% |
| FTSE RAFI US 1500 Small/Mid Invesco ETF | ||
| VTWV | 0.01% | -7.97% |
| Russell 2000 Value Vanguard | ||
| 3rd Resistance Point | 0.7318 |
| 2nd Resistance Point | 0.7129 |
| 1st Resistance Point | 0.6751 |
| Last Price | 0.6373 |
| 1st Support Level | 0.6184 |
| 2nd Support Level | 0.5995 |
| 3rd Support Level | 0.5617 |
| 52-Week High | 1.9280 |
| Fibonacci 61.8% | 1.4350 |
| Fibonacci 50% | 1.2826 |
| Fibonacci 38.2% | 1.1303 |
| Last Price | 0.6373 |
| 52-Week Low | 0.6373 |
Please check your inbox for a link to activate your My Barchart Account.
If you do not receive the email within a few minutes check your spam folder or contact our support team for assistance.
